Menu Search
Equities

QuantumPharm Inc

2228:HKG

QuantumPharm Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)13.10
  • Today's Change0.06 / 0.46%
  • Shares traded5.51m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year QuantumPharm Inc had net income fall 33.08% from a loss of 1.44bn to a larger loss of 1.91bn despite a 30.80% increase in revenues from 133.35m to 174.42m. An increase in the selling, general and administrative costs as a percentage of sales from 207.94% to 224.87% was a component in the falling net income despite rising revenues.
Gross margin--
Net profit margin-1,280.46%
Operating margin-345.13%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in CNYView more

In 2023, QuantumPharm Inc increased its cash reserves by 23.78%, or 136.54m. Cash Flow from Investing totalled 735.58m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 567.56m for operations while cash used for financing totalled 25.89m.
Cash flow per share-1.26
Price/Cash flow per share--
Book value per share1.33
Tangible book value per share1.32
More ▼

Balance sheet in CNYView more

QuantumPharm Inc uses little debt in its capital structure as supported by a debt to capital ratio of 3.80%.
Current ratio15.68
Quick ratio--
Total debt/total equity0.0397
Total debt/total capital0.038
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.